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Abstract
Background: Although cyclosporin is effective in severe ulcerative colitis (UC), long-term colectomy rate varies between
60 and 88% among patients in whom cyclosporin initially induced remission. The aim of our study was to evaluate the long-
term outcome and the optimal duration of cyclosporin therapy in acute, severe UC.
Methods: A total of 73 patients underwent i.v. cyclosporin therapy for a steroid refractory flare up of UC between 1998 and
2009. All patients were treated with 1mg/kg i.v. methylprednisolone for 3–7 days before the administration of cyclosporin.
Patients received i.v. cyclosporin of 4–5mg/kg for 5 days following oral treatment.
Results: The mean follow up after the initiation of cyclosporin was 4.2 years. There were 20 patients who underwent early
colectomy. Cyclosporin had to be discontinued due to side effects in 22 patients. Cyclosporin failed and late colectomy was
performed in 14 of the 53 responders. Duration of cyclosporin treatment was significantly longer in those who avoided
colectomy. The probability of avoiding colectomy proved to be 66% in case of 1-year treatment period with cyclosporin. The
longer treatment period resulted in longer colectomy-free disease course.
Conclusions: Cyclosporin is effective in acute, severe UC during long-term follow up. Our data suggest that the longer
cyclosporin is used, the more it is possible to avoid colectomy in the future.
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Introduction
The main goal of treatment of ulcerative colitis (UC) is
to induce and maintain steroid-free remission, improve
the quality of life, and reduce the risks of colectomy.
Corticosteroids have been the primary therapies in
moderate to severe UC for years. Those who fail to
respond to treatment with corticosteroids, or who pre-
sent with severely active UC, should be considered as
candidates for rescue treatment.1 Our previous work
revealed that anaemia, need for blood transfusion,
and frequency of previous hospitalizations signiﬁcantly
determines the response to early parenteral corticoster-
oid therapy. Colectomy rate was 2.5-times higher in
patients refractory to i.v. steroid therapy, which may
determine both the early and late outcome and the col-
ectomy rate of acute, severe UC.2
Cyclosporin is one of the most eﬀective therapeutic
choice in patients with severe UC; however, long-term
colectomy rate still varies between 60–88% among
patients in whom cyclosporin initially induced remis-
sion.3 The early disappointing long-term results and
the serious side eﬀects limit the widespread use of cyclo-
sporin in the era of inﬂiximab; however, it serves as a
rapidly acting ‘bridge’ to maintenance therapy with the
slowly acting agents azathioprine or mercaptopurine.4
Although the optimal duration of cyclosporin treat-
ment is unknown, it is usually discontinued within
3 months.5
Since data on long-term eﬃcacy of cyclosporin are
still controversial and the optimal duration of therapy
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is unknown the aim of our study was to retrospectively
evaluate the long-term eﬃcacy and safety of cyclo-
sporin therapy in patients with acute, steroid-refractory
severe UC.
Patients and methods
Patient population
All patients who underwent i.v. cyclosporin therapy in
our tertiary clinic for a steroid refractory ﬂare up of
severe UC between January 1998 and June 2009 were
identiﬁed from our database. Deﬁnition of steroid
refractoriness was set up according to the ECCO
guideline.6 A total of 73 patients (40 females, 33
males; mean age at diagnosis 31.7 years, mean disease
duration 13.4 years) fulﬁlled the inclusion criteria. The
patients’ medical records were collected continuously
in an IBD database developed by us. The median
Lichtiger score was 12 (interquartile range 9–14) at
the start of cyclosporin therapy Data were analysed
retrospectively in September 2012. We reviewed the
age, gender, disease duration, disease extent, concomi-
tant azathioprine/mercaptopurine use, the dose and
duration of cyclosporin therapy, the frequency of
side eﬀects, the need for inﬂiximab therapy after dis-
continuation of cyclosporin, and the frequency of col-
ectomy. The demographics of the patients are detailed
in Table 1. Twenty-seven patients received thiopurine
therapy before the administration of cyclosporin. The
mean length of follow up was 4.2 years. Cyclosporin
was stopped in case of clinical remission, intolerable
side eﬀects or loss of response. Disease activity was
regularly deﬁned by Lichtiger score. Lichtiger score
2 was considered remission.
Administration of cyclosporin
All patients were treated with 1mg/kg i.v. methylpred-
nisolone for 3–7 days before the administration
of cyclosporin. Patients received i.v. cyclosporin of
4–5mg/kg for 5 days following oral treatment at the
same starting dose in the case of a good initial response.
Cyclosporin levels were closely monitored, and the dose
was adjusted to maintain fasting levels between
150 and 300 ng/ml and 2 hours post-dosing level of
800–1200 ng/ml. When starting cyclosporin therapy,
we planned to use it at least for 6 months.
Twenty-seven patients received concomitant
immunosuppression (26 thiopurines, one mycopheno-
late mofetil) before cyclosporin therapy. None of the
patients was treated with inﬂiximab before cyclosporin
therapy.
Statistical analysis
Data analysis was carried out using Student t-test and
Wilcoxon test. Proportions were analysed using
Pearson’s chi-squared test, Fisher’s exact test.
Kaplan–Meier survival curves were plotted for analysis
with the log-rank and Breslow tests. Cox regression was
applied to investigate the relationship between the
cyclosporin treatment period and the risk of colectomy.
p< 0.05 was considered statistically signiﬁcant.
For statistical analysis, SPSS version 15.0 (SPSS,
Chicago, IL, USA) was used.
Results
Short and long-term efficacy of cyclosporin
therapy
In this study, 53/73 (73%) patients initially responded
to i.v. cyclosporin. Twenty (27%) patients underwent
early colectomy within 3 months. During the >4-year
follow-up period, 14 of the 53 responder patients (26%)
underwent late colectomy. Cyclosporin had to be dis-
continued because of intolerable or severe side eﬀects in
22/53 (42%) patients. The mortality rate was 0%.
Overall, colectomy free survival was 53%. Five
patients were switched to inﬂiximab after cyclosporin
failure. For maintenance therapy, azathioprine was
given for 24 patients, 5-aminosalicylic acid for
18 patients, and inﬂiximab for seven patients who
avoided colectomy.
Figure 1 shows the outcomes of the rescue
cyclosporin therapy in acute, severe UC patients.
The demographic and clinical data of patients who
underwent and who avoided surgery are detailed
in Table 2.
Table 1. Demographics of the patients
Characteristic
Ulcerative colitis
(n¼ 73)
Age at diagnosis (years) 44.6 (22–74)
Disease duration (years) 13.4 (3–42)
Gender (female/male) 40/33
Left-sided colitis/extensive colitis 28/45
Concomitant azathioprine or mercaptopurine 27
Body mass index (kg/m2) 23.6 (15.2–38.3)
Dose of cyclosporin (mg/kg) 4.7
Length of follow up (years) 4.2
Values are mean (range), n, or mean.
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Duration of cyclosporin therapy
Duration of cyclosporin therapy was signiﬁcantly
shorter in those responder patients who underwent
late colectomy vs. those who avoided surgery (5.4 vs.
13.3 months, p¼ 0.009; Figure 2). If patients were trea-
ted for a year, the probability of avoiding colectomy
proved to be 66%. The longer treatment period
decreased the risk of colectomy in the Cox regression
model (hazard rate ratio 0.98, p¼ 0.013). The mean
time elapsed between the discontinuation of cyclo-
sporin therapy and colectomy was 9 months (0.1–72
months. Patients who underwent late colectomy were
operated on an average of 22 months after stopping
cyclosporin. Cyclosporin was discontinued because of
side eﬀects in 53% of these patients and because of loss
of response in 43%. Patients who avoided colectomy
were in remission, deﬁned as Lichtiger score 2, for an
average of 12.7 months before stopping cyclosporin. Of
these patients, azathioprine was given for 24 and inﬂix-
imab for seven patients for maintaining remission after
the cyclosporin therapy.
Side effects
The types of major side eﬀects occurring during cyclo-
sporin therapy are summarized in Table 3. Side eﬀects
occurred in 52 patients (72%) during the therapy. The
most frequent side eﬀects were hypertension (21%),
tremor (19%), hypertrichosis (14%), myalgia and
muscle cramping (15 and 6%), and numbness of legs
(8%). Nephro- or hepatotoxicity occurred in seven
73 patients with acute severe UC 
not responding to iv. steroid 
20 (27%) early colectomy
cyclosporine therapy 
53 (73%) responders 
14 (26%) late colectomy 
39 (53%) colectomy-free 
24 (61%) thiopuine maintenance therapy 
15 (38%) on thiopurine therapy 
3 (21%) on thiopurine therapy 
9 (45%) on thiopurine therapy 
Figure 1. Outcomes of the rescue cyclosporin therapy in acute, severe UC patients.
Table 2. Demographic and clinical data of patients
Characteristic Colectomized (n¼ 34) Colectomy free (n¼ 39)
Age at diagnosis (years) 32.4 (14–69) 31.3 (16–63)
Disease duration (years) 12.8 (3–42) 14 (3–36)
Gender (female/male) 19/15 20/19
Left-sided colitis/extensive colitis 10/24 20/19
Concomitant azathioprine/mercaptopurine 12 15
Body mass index (kg/m2) 22.2 (15.2–33.3) 24.9 (16–38.2)
Duration of cyclosporin therapy (months) 5.4 (0.1–41) 13.3 (0.1–60)
Side effects 19 18
Values are mean (range), n, or mean.
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patients (14%). Increased serum cholesterol levels were
detected in 47.2% of the patients. The major side eﬀects
resulting in the discontinuation of cyclosporin therapy
occurred in 22 patients. The most frequent were mus-
culoskeletal adverse reactions (47%) and hypertension
(42%), then neurological side eﬀects (37%), gastro-
intestinal side eﬀects (26%), skin side eﬀects (16%),
and malaise (5%).
Discussion
This retrospective study conﬁrmed that cyclosporin is
eﬀective in the treatment of acute, severe UC during the
long-term follow up. Overall, colectomy free survival
was 53% during the >4-year follow-up period.
Colectomy-free survival signiﬁcantly increased in case
of longer duration of cyclosporin therapy. If patients
were treated for a year, the probability to avoid colec-
tomy proved to be 66%.
The published data about the short and long-term
results of cyclosporin therapy are various and contro-
versial – maybe due to the small patient numbers and
the diﬀerence in the duration of therapy. Recently,
some studies tried to obtain a coherent view and exam-
ined the long-term outcome of cyclosporin therapy. In
the study of Mocciaro et al.7 the colectomy rate was
29% at 3 months and 48% at 12 months in 35 cyclos-
porin-treated UC patients. The 2–3-year cumulative
colectomy rates were 54% and 57%. In this study,
cyclosporin was administered for a maximum of 3
months. Data from the UK revealed 42% of UC
patients undergoing colectomy during a median
follow up of 3.8 years.8 In a Japanese study, the overall
percentages of patients who had not required surgery
were 72% at 1 year, 62% at 2 years, 58% at 3 years,
and 48% at 5 years.9 Unfortunately, these papers do
not clarify the duration of cyclosporin therapy.
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Figure 2. Kaplan–Meier plot showing the need for colectomy in relation to the duration of cyclosporin therapy.
Table 3. Major side effects occurring during
cyclosporin therapy
Type of side effects
Patients
(n¼ 37)
Disturbance of sensation 2
Gastrointestinal side effects 3
Liver function abnormalities 3
Gingivitis, gingiva hyperplasia 3
Numbness of extremities 4
Myalgia 4
Alopecia 5
Hypertrichosis 8
Tremor, muscle spasm 11
Hypertension 11
Values are n.
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Cheifetz et al.10 treated 71 patients with cyclosporin
and followed them up for a mean of 3 years.
Cumulative colectomy rates were 39% at 1 year, 42%
at 2 years, and 46% at 5 years. Cyclosporin was dis-
continued in most patients by 6 months.
In general, cyclosporin is used for inducing remis-
sion as a rescue therapy and the optimal duration of
the therapy is unknown.11 In our study, the colectomy
rate after 4 years was 47%. The mean duration of
cyclosporin therapy was more than 13 months in colect-
omy-free patients. Our results showed that two-thirds
of patients can avoid colectomy if treated with cyclo-
sporin for at least 12 months. In a recent paper of
Sjo¨berg et al.,12 cyclosporin was given for a mean of
4.5 months: at 12 months, 77% of the patients
remained colectomy-free; however, this study was not
followed up for more than 1 year.
Concerns of toxicity remain the main reasons for
underusing cyclosporin in the clinical practice.
However, all of the studies mentioned above found
the majority of the adverse events to be mild.
Sternthal et al.13 revealed major adverse events in
15% of their patients. Nephrotoxicity occurred in 5%
of the patients. Serious infection occurred in 6%. seiz-
ures in 4%, anaphylaxis in 1%, and death in 2%. The
most common minor adverse events were paresthesias,
hypomagnesemia, hypertension, and hypertrichosis.13
In our study, more than 70% of patients developed
mild or moderate side eﬀects and 60% of them resulted
in the discontinuation of the therapy.
The main limitation of this study is the retrospective
nature. However, the data compared in the study are
quite reliable and they come from a single centre with
an interest in the management of severe UC.
In summary, our data show similar long-term out-
come of cyclosporin therapy than the recent studies.
Cyclosporin seems to be eﬀective in acute, severe UC
during long-term follow up. Although the optimal dur-
ation for the treatment is unknown, our data suggest
that the longer cyclosporin is used, the more it is pos-
sible to avoid colectomy in the future. Multicentre trials
would be needed to conﬁrm the optimal duration for
cyclosporin.
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